INS and Hypoglycemia: It should be mentioned that although dapagliflozin, used in Tamborlane et al. and T2NOW, has a low propensity to cause hypoglycemia when used as monotherapy or in combination with most other glucose-lowering drugs, it carries an increased risk of this adverse event when combined with insulin [33].